ArticleJournal of neuro-oncology2025
Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMalignant glioma patients face unique end-of-life (EOL) challenges due to their aggressive disease course and early neurocognitive decline. This study aimed to compare EOL patterns between patients with malignant glioma and those with solid tumors referred for palliative care (PC).
methodsWe conducted a retrospective cohort study of adults with malignant glioma or five major solid tumors (lung, colorectal, gastric, liver, and pancreato-biliary) who received PC consultation at a South Korean tertiary hospital (2018-2022). Clinical data were linked to the National Health Insurance Service database. Outcomes included documentation of advance care planning (ACP) elements, healthcare utilization, and place of death, which were analyzed using multivariable regression.
resultsCompared with 4,283 individuals with solid tumors, those with malignant glioma (n = 229) were younger and referred to PC earlier. ACP documentation was substantially lower (20.1% vs. 58.0%; aOR, 0.13; 95% CI, 0.09-0.19), and only 21.4% of life-sustaining treatment decisions were documented as patient-determined versus 67.1% in solid tumors (aOR, 0.07; 95% CI, 0.04-0.12). Malignant glioma was also associated with fewer emergency visits (29.3% vs. 48.7%) and less chemotherapy (29.7% vs. 42.0%) but lower hospice use (62.0% vs. 73.1%; aOR, 0.57; 95% CI, 0.43-0.77). Medical costs were higher six months before death but lower in the final month among patients with malignant glioma compared with those with solid tumors. Death occurred more often in nursing care hospitals (20.5% vs. 6.8%, p < 0.0001) or at home/non-hospital settings (15.3% vs. 10.0%, p = 0.0106).
conclusionIn this single-center cohort, malignant glioma patients were less likely to have documented ACP elements and more likely to die in nursing hospitals than those with solid tumors. Early ACP and tailored palliative strategies are essential.
Indexed as
Identifiers
41460550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.